These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

445 related items for PubMed ID: 33813594

  • 1. Can 68Ga-PSMA-11 PET/CT predict pathological upgrading of prostate cancer from MRI-targeted biopsy to radical prostatectomy?
    Yin H, Chen M, Qiu X, Qiu L, Gao J, Li D, Fu Y, Huang H, Guo S, Zhang Q, Ai S, Wang F, Guo H.
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3693-3701. PubMed ID: 33813594
    [Abstract] [Full Text] [Related]

  • 2. The role of PSMA PET/CT to predict upgrading in patients undergoing radical prostatectomy for ISUP grade group 1 prostate cancer.
    Esen B, Seymen H, Gurses B, Armutlu A, Koseoglu E, Tarim K, Ertoy Baydar D, Sarikaya AF, Canda AE, Balbay D, Kordan Y, Tilki D, Esen T, Demirkol MO.
    Prostate; 2024 Jan; 84(1):32-38. PubMed ID: 37661579
    [Abstract] [Full Text] [Related]

  • 3. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68 Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.
    Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, McEwan L, Wong D, Delahunt B, Egevad L, Samaratunga H, Brown N, Parkinson R, Roberts MJ, Yaxley JW.
    BJU Int; 2021 Jan; 127(1):71-79. PubMed ID: 32524748
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Dual-tracer PET/CT-targeted, mpMRI-targeted, systematic biopsy, and combined biopsy for the diagnosis of prostate cancer: a pilot study.
    Qiu DX, Li J, Zhang JW, Chen MF, Gao XM, Tang YX, Zhang Y, Yi XP, Yin HL, Gan Y, Wang GL, Zu XB, Hu S, Cai Y.
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2821-2832. PubMed ID: 34860277
    [Abstract] [Full Text] [Related]

  • 10. Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients.
    Spohn S, Jaegle C, Fassbender TF, Sprave T, Gkika E, Nicolay NH, Bock M, Ruf J, Benndorf M, Gratzke C, Grosu AL, Zamboglou C.
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192
    [Abstract] [Full Text] [Related]

  • 11. Incremental Impact of [68 Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.
    Szigeti F, Schweighofer-Zwink G, Meissnitzer M, Hauser-Kronberger C, Hitzl W, Kunit T, Forstner R, Pirich C, Beheshti M.
    Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
    [Abstract] [Full Text] [Related]

  • 12. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.
    Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, Shariat SF, Montorsi F, Briganti A.
    Eur Urol Oncol; 2024 Apr; 7(2):231-240. PubMed ID: 37689506
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Diagnostic ability of Ga-68 PSMA PET to detect dominant and non-dominant tumors, upgrading and adverse pathology in patients with PIRADS 4-5 index lesions undergoing radical prostatectomy.
    Koseoglu E, Kordan Y, Kilic M, Sal O, Seymen H, Kiremit MC, Armutlu A, Ertoy Baydar D, Altinmakas E, Vural M, Falay O, Canda AE, Balbay D, Demirkol MO, Esen T.
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):202-209. PubMed ID: 32826958
    [Abstract] [Full Text] [Related]

  • 18. Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.
    van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.
    BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
    [Abstract] [Full Text] [Related]

  • 19. Pilot study of the diagnostic utility of 89 Zr-df-IAB2M and 68 Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Vlachostergios PJ, Niaz MJ, Thomas C, Christos PJ, Osborne JR, Margolis DJA, Khani F, Bander NH, Scherr DS, Tagawa ST.
    Prostate; 2022 Mar; 82(4):483-492. PubMed ID: 34985786
    [Abstract] [Full Text] [Related]

  • 20. Detection Rate of 68Ga-PSMA PET/CT vs. mpMRI Targeted Biopsy for Clinically Significant Prostate Cancer.
    Pepe P, Pepe L, Cosentino S, Ippolito M, Pennisi M, Fraggetta F.
    Anticancer Res; 2022 Jun; 42(6):3011-3015. PubMed ID: 35641295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.